Amherst Laboratories, Inc.

AMHERST LABORATORIES, INC. (ALI) is a pharmaceutical toll manufacturing company that started operation on March 2007 with its Solids Plant and expanded with a new Liquids Plant on April 2010. This new pharmaceutical plant is a state-of-the-art facility, designed to produce a variety of products including prescription medicines in major therapeutic categories in tablet, capsule, powder, ointments, and non-steroidal creams format and liquids products in syrup, suspension, and drops format. Many of these products are leading brands in the Philippines, Indonesia, Thailand, Malaysia, Singapore, Hongkong, Vietnam and Myanmar. ALI stands as a testament of the commitment of its late founder, Mr. Jose Y. Campos, to provide affordable health care to all Filipinos. It is also the company’s response to a rapidly changing landscape due to globalization and harmonization of regulatory standards in pharmaceuticals. * A Stand-alone Facility ALI has complete utility systems which include, among others, a single floor interstitial machine room, a warehouse, a two-storey administration building that houses a multipurpose room, training rooms, employees’ cafeteria and locker amenities, and its own Quality Control Laboratory and Quality Assurance Operations. The Plant manages end-to-end manufacturing process from transfer of technology to delivery of finished goods. It also gives value-added services to its customers by providing Quality Assurance Services such as inspection and release of incoming materials, semi-finished goods, and finished goods and Post-manufacturing Services such as stability studies, periodic product review, and documentation management. * Quality Commitment and World-class Status Amherst Laboratories has obtained the European Union-Good Manufacturing Practice (EU-GMP) certification—a first for any pharmaceutical manufacturing facility in the Philippines. The certification came through the European Medicines Agency (EMEA), a decentralized body of the EU which protects and promotes public health through the evaluation of medicines being sold in EU member-states. The EU-GMP certification signifies the manufacturing facility’s compliance with EU’s standards on the quality, safety, and efficacy of the medicines it produces. Tantamount to a license to sell, the EMEA certification gives ALI the opportunity to manufacture for and export its products to member-states of the EU, as well as Iceland, Liechtenstein, and Norway. Aside from the EU-GMP certification, ALI has also obtained a certificate of current Good Manufacturing Practice (cGMP) from the Philippine Food and Drug Administration (Philippine FDA). ALI also complies with the tight regulatory requirements brought about by the ongoing regulatory harmonization in Southeast Asia.